LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Fineberg, N; Stein, DJ; Premkumar, P; Carey, P; Sivakumaran, T; Vythilingum, B; Seedat, S; Westenberg, H; Denys, D (2006)
Publisher: Lippincott, Williams and Wilkins
Languages: English
Types: Article
Subjects:
Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive–compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized placebo-controlled studies looking at the addition of the second-generation antipsychotic quetiapine in such cases. Three studies fulfilled the inclusion criteria. Altogether 102 individuals were subjected to analysis using Review Manager (4.2.7). The results showed evidence of efficacy for adjunctive quetiapine (< 400 mg/day) on the primary efficacy criterion, measured as changes from baseline in total Yale–Brown Obsessive Compulsive Scale scores (P = 0.008), the clinical significance of which was limited by between-study heterogeneity. The mechanism underlying the effect may involve serotonin and/or dopamine neurotransmission.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002). Quetiapine augmentation in patients with treatment-resistant obsessive compulsive disorder. A single blind, placebo-controlled study. Int Clin Psychopharmacol 17:115-119.
    • Bogan AM, Koran LM, Chuong HV, Vapnik T, Bystritsky A (2005). Quetiapine augmentation in obsessive compulsive disorder resistant to serotonin reuptake inhibitors: an open label study. J Clin Psychiatry 66:73-79.
    • Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ (2005). Quetiapine augmentation of SRIs in treatment refractory obsessivecompulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry 5:5.
    • Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005). The use of aripiprazole in obsessive compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66:49-51.
    • Cochrane Collaboration (2004). Review Manager 4.2.7. Available at: http:// www.cc-ims.net/RevMan.
    • Denys D, van Megen H, Westenberg H (2002). Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment refractory obsessive compulsive disorder; an open label study. J Clin Psychiatry 63:700-703.
    • Denys D, de Geus F, van Megen HJGM, Westenberg HGM (2004a). A doubleblind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
    • Denys D, Klompmakers AA, Westenberg HG (2004b). Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berlin) 176:195-203.
    • Eddy KT, Dutra L, Bradley R, Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24:1011-030.
    • Fineberg NA, Gale T (2005). Evidence-based pharmacological treatments for obsessive compulsive disorder. Int J Neuropsychopharmacol 8:107-129.
    • Fineberg NA, Sivakumaran T, Roberts A, Gale T (2005). Adding quetiapine to SRI in treatment resistant obsessive compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 20:223-226.
    • Fineberg NA, Gale T, Sivakumaran T (2006). A review of antipsychotics in treatment resistant obsessive compulsive disorder (OCD). J Psychopharmacol 20:97-103.
    • Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989). The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
    • Guy W (1976). ECDEU assessment manual for psychopharmacology (revised). Bethesda, Marland: US Department of Health, Education and Welfare.
    • Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
    • Leon AC, Shear MK, Portera L, Klerman GL (1992). Assessing impairment in patients with panic disorder: The Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78-82.
    • Maina G, Albert U, Ziero S, Bogetto F (2003). Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol 18:23-28.
    • March JS, Frances A, Kahn DA, Carpenter D (1997). The Expert Consensus Guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(Suppl):1-72.
    • Marek GJ, Carpenter LL, McDougle CJ, Price LH (2003). Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28:402-412.
    • McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR (1990). Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 147:652-654.
    • McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
    • McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH (1995). Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 152:423-429.
    • Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
    • Mohr N, Vythilingum B, Emsley RA, Stein DJ (2002). Quetiapine augmentation of serotonin reuptake inhibitors in obsessive compulsive disorder. Int Clin Psychopharmacol 17:37-40.
    • Sevincok L, Topuz A (2003). Lack of efficacy of low dose quetiapine addition in refractory obsessive compulsive disorder. J Clin Psychopharmacol 23:448-450.
    • Toren P, Ratner S, Laor N, Weizman A (2004). Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safe 27:1135-1156.
    • Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP (2000). Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250-262.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article